In 2005, the USA Food and Drug Administration (FDA) warned that patients with UGT1A1*28/*28 genotype are at increased risk for neutropenia when irinotecan is used, and a lower starting dose of irinotecan was recommended for UGT1A1*28/*28 homozygotes [27]. This evidence concerns the gene UGT1A1 and neutropenia.